Loading...
XNASOMER
Market cap512mUSD
Jan 10, Last price  
8.84USD
1D
-10.62%
1Q
125.51%
Jan 2017
-10.89%
IPO
4.49%
Name

Omeros Corp

Chart & Performance

D1W1MN
XNAS:OMER chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
5.25%
Rev. gr., 5y
0.87%
Revenues
0k
200,0001,923,0001,170,0001,444,0002,105,0004,524,0006,022,0001,600,000539,00013,509,00041,617,00064,826,00029,868,000111,805,00073,813,000000
Net income
-118m
L
-22,777,000-23,091,000-23,827,000-21,089,000-29,251,000-28,546,000-38,444,000-39,796,000-73,673,000-75,096,000-66,745,000-53,481,000-126,757,000-106,906,000-138,061,000194,235,00028,777,000-117,813,000
CFO
75m
P
-10,172,000-14,314,000-19,673,000-19,027,000-14,502,000-25,668,000-34,551,000-29,695,000-58,044,000-65,209,000-51,504,000-36,227,000-103,737,000-60,073,000-100,086,000-109,722,000-86,483,00074,726,000
Earnings
May 13, 2025

Profile

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
URL
https://www.omeros.com/
IPO date
Oct 08, 2009
Employees
196
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
184,649
164,344
Unusual Expense (Income)
NOPBT
(184,649)
(164,344)
NOPBT Margin
Operating Taxes
(210,806)
Tax Rate
NOPAT
(184,649)
46,462
Net income
(117,813)
-509.40%
28,777
-85.18%
Dividends
Dividend yield
Proceeds from repurchase of equity
(4,504)
415
BB yield
2.20%
-0.29%
Debt
Debt current
13,736
98,691
Long-term debt
371,151
270,068
Deferred revenue
Other long-term liabilities
2,088
125,270
Net debt
213,039
49,362
Cash flow
Cash from operating activities
74,726
(86,483)
CAPEX
(426)
(113)
Cash from investing activities
27,454
(127,564)
Cash from financing activities
(106,084)
124,248
FCF
21,880
(113,022)
Balance
Cash
171,848
194,918
Long term investments
124,479
Excess cash
171,848
319,397
Stockholders' equity
(752,919)
85,684
Invested Capital
1,091,608
462,422
ROIC
6.13%
ROCE
EV
Common stock shares outstanding
62,739
62,737
Price
3.27
44.69%
2.26
-64.85%
Market cap
205,157
44.70%
141,786
-64.63%
EV
418,196
191,148
EBITDA
(183,729)
(163,392)
EV/EBITDA
Interest
14,502
22,702
Interest/NOPBT